



ImmunoScape Announces Chief Business Officer to Lead U.S. Expansion

Biotech executive Geoff Nosrati, Ph.D. has been named Chief Business Officer as the company expands to San Diego to accommodate growing list of U.S. partnerships

SINGAPORE and SAN DIEGO – February 23, 2021 – [ImmunoScape](https://immunoscape.com/), a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced the company has established its U.S. headquarters in San Diego and brought on experienced biotech executive Geoff Nosrati, Ph.D. to lead the expansion as Chief Business Officer.

Before joining ImmunoScape, Dr. Nosrati advised biotechnology clients at McKinsey & Co., with a focus on corporate strategy, finance, due diligence and M&A. He most recently held senior executive positions at Aduro Biotech, a company focused on development of therapies for both oncology and renal disease, where he led strategy and corporate development. Dr. Nosrati holds a Ph.D. in Biochemistry and Molecular Biology from the University of California, Los Angeles and graduated with a B.S. in Chemistry from Duke University.

Dr. Nosrati's experience executing corporate expansion strategies will prove invaluable as ImmunoScape seeks to build upon its growing list of partnerships with U.S.-based academic and industry leaders. These partnerships will also leverage a world-class scientific team that ImmunoScape is building to run the new San Diego laboratory that will expand the company's overall capacity.

"The ImmunoScape team has created a platform that I believe has the potential to transform the way we think about immunotherapy and identify new treatments," said Geoff Nosrati, Chief Business Officer at ImmunoScape. "I look forward to further expanding the use of this breakthrough technology with new partners across the biotech space and growing ImmunoScape's U.S. presence."

ImmunoScape's Deep Immunomics platform enables the characterization of a patient's immunome at ultra-high resolution. ImmunoScape has delivered these insights to leading biopharma and academic partners to aid drug development efforts within multiple therapeutic areas, including immuno-oncology, infectious disease, and autoimmune disease. As the Singapore-founded company continued to forge new partnerships with U.S.-based collaborators, the need for a permanent presence and team became essential.

"Over the last several years, we've built up an impressive roster of partnerships and proven the value of our technology, especially with high-profile academic, medical and industry organizations in the United States," said Choon Peng Ng, CEO of ImmunoScape. "With Geoff at the helm, our new laboratory and U.S. base will allow us to form deeper relationships with the biotech leaders that can utilize the insights from our platform."

To learn more about ImmunoScape please visit <https://immunoscape.com/>.

About ImmunoScape

ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The



company's Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. For more information, please visit <https://immunoscape.com/>.

Media Contact

Kalyn Schieffer

kos@anzupartners.com